Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALKS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aripiprazole Lauroxil FDA approved Oct 2015 · Aristada |
Schizophrenia | Phase 4 · NCT04203056 | Terminated |
| Naltrexone FDA approved Apr 2006 · Vivitrol |
Opioid-Related Disorders | Phase 4 · NCT02978417 | Completed |
| Olanzapine And Samidorphan L-Malate FDA approved May 2021 · Lybalvi |
Focus of Study is on Healthy Lactating Women | Phase 1 · NCT05547100 | Completed |
| XR-NTX | Alcohol Use Disorder | Phase 4 · NCT05028062 | Recruiting |
| Norepinephrine Reuptake Inhibitor | Schizophrenia | Phase 4 · NCT04203056 | Terminated |
| ALKS 2680 | Narcolepsy Type 1 | Phase 2/3 · NCT06767683 | Recruiting |
| S-Adenosylmethionine | Schizophrenia | Phase 3 · NCT05303064 | Recruiting |
| ALKS 5461 | Major Depressive Disorder | Phase 3 · NCT02158533 | Completed |
| injected insulin | Diabetes Mellitus | Phase 3 · NCT00157339 | Completed |
| Injectable insulin | Diabetes Mellitus, Type 2 | Phase 3 · NCT00325364 | Completed |
| Human Insulin Inhalation Powder | Diabetes Mellitus | Phase 3 · NCT00157339 | Completed |
| Naloxone | Heroin Dependence | Phase 3 · NCT03711318 | Terminated |
| Alixorexton | Narcolepsy Type 2 | Phase 3 · NCT07502443 | Recruiting |
| ALKS 8700 | Multiple Sclerosis | Phase 3 · NCT02634307 | Completed |
| ALKS 3831 | Schizophrenia | Phase 3 · NCT03201757 | Completed |
| Active Cannabis | Cannabis | Phase 2 · NCT04576507 | Completed |
Also used in these trials (approved or third-party drugs, not ALKS's own candidates): Paliperidone Palmitate, Olanzapine, Insulin Glargine, Dimethyl Fumarate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALKS holds $787.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALKS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 10,012,267 | 5.96% | 2025-12-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 9,647,056 | 5.74% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 8,676,888 | 5.16% | 2026-03-31 |
| Blair Curtis Jackson President & CEO, Alkermes plc, Director · +263,283 options |
Insider | 241,308 | 0.14% | 2026-02-26 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. · +114,656 options |
Insider | 219,353 | 0.13% | 2026-11-03 |
| Shane Cooke Director · +16,947 options |
Insider | 106,679 | 0.06% | 2026-05-20 |
| Christian Todd Nichols SVP, Chief Commercial Officer · +97,284 options |
Insider | 102,193 | 0.06% | 2026-08-17 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer · +184,133 options |
Insider | 65,389 | 0.04% | 2026-09-01 |
| Brian P Mckeon Director · +11,538 options |
Insider | 48,536 | 0.03% | 2026-05-20 |
| nancy lynn MD snyderman Director · +11,538 options |
Insider | 36,178 | 0.02% | 2026-08-03 |
| Richard Gaynor Director · +11,538 options |
Insider | 35,751 | 0.02% | 2026-05-20 |
| Frank Anders Wilson Director · +11,538 options |
Insider | 35,751 | 0.02% | 2026-05-20 |
Share count 168,043,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALKS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →